Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
about
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineHaematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest ChinaPhiladelphia positive acute lymphoblastic leukaemia of childhood.Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice.Imatinib mesylate in the treatment of hematologic malignancies.A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group studyUKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia.Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemiaMolecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T-cell phenotype.Advances in adult acute lymphoblastic leukemia therapy.High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia.Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice.Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy
P2860
Q27000078-7E2406E3-F627-498A-AAF3-3C518D8EA2B5Q33414592-C1DAF2B8-88BC-44DE-A1F2-18DB6A75B3A1Q33587563-47EB3510-6E80-4F0E-8422-7A7B46DB0E9DQ33843477-19CCFFEE-E621-473C-B45B-60524D4973EAQ34454611-B96D5AC8-95C2-4737-AFE0-3DB9D6BDF530Q34810036-71952FED-8F79-473E-B99B-7FDE48536F2CQ35602127-2C71455A-2999-4DC1-B5B7-57D32534DE31Q35888941-A3A0D0E4-C800-4AE6-A7F2-CA77284BB45BQ36228062-E30D5E51-00E6-4FAB-8620-1693DDAAF17DQ36600241-55AF537A-6217-4AB3-BD3F-18EB566B9970Q36616666-B7087515-BF8E-4339-955D-2E9E32452DABQ36634604-5A57D382-BB5C-4818-8225-9AB03A33B0D2Q36960525-499756E6-7354-48F4-963B-1B64E0672261Q36979320-983BACAA-6805-4400-BE3B-D7E316846DC3Q36984852-08FA4B68-8ECC-48B9-81F3-3E378086D93AQ37152745-08A29A28-36E5-4276-90C7-21510163CE71Q37360559-FBAE0B5D-0055-4543-B8ED-C0FC8258EC9AQ37412290-665250E5-81E2-4E9A-AF80-D68DFCE9B3F7Q37564762-5C8A6B1F-9BA3-47CF-84BD-84D1BC800CEDQ37613888-B53CE8FE-B965-41FA-A8D8-9646034D4A05Q37619813-F29C3592-828D-43E6-B41F-C2532A22957BQ37836938-BB40B2D2-79FC-4EA5-89DD-B215CD51A73AQ38044901-84AEB712-52DB-4B3B-B827-57D3FBB7465DQ38207017-6ED1E65D-5987-4D45-9C05-F1E3497D5B4BQ38423781-10115495-2570-4545-BE60-9E61F5E9C0B5Q38734309-B085C849-9F8A-47AE-9AAA-BB808EDE3692Q38759431-E702CFA3-8AA8-4C7C-83C2-0EF22D3B2B7BQ39010282-40B148B6-C712-4AEB-86B5-4C8DE4BA17C9Q39112294-293FC97C-F1DF-45E5-9C76-8DA5E869B595Q39402662-9FFA7B03-3BCA-417A-A69C-8F11B5DAA420Q39459190-16116EC2-79BF-46F1-A3D1-14E38DE7004CQ40044204-C4866CD3-1F10-4EC4-8B24-5FB76476E506Q40083551-EC05749D-08CC-478F-9991-E384A1CB83C9Q40230301-60775719-4B42-4386-8265-64EAABCEE8E8Q40365473-668E3BD3-6956-470D-9107-A18C4161BC03Q40433924-F56E8A6F-313E-4795-8A85-A30F4E076CC2Q41008753-93D198DC-93B4-422E-93DF-AA4E799E6D01Q41594071-C969819F-6A6D-48FA-A5F7-D0F886ED4CA2Q41840259-5B416371-FF5E-44C7-B041-DAEEB4CDA828Q41863632-1DAF1701-71FC-4960-80C3-1B99547AD3CA
P2860
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@en
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@nl
type
label
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@en
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@nl
prefLabel
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@en
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@nl
P2093
P1433
P1476
Combination of intensive chemo ...... acute lymphoblastic leukemia.
@en
P2093
Fumiharu Yagasaki
Isamu Sugiura
Itsuro Jinnai
Japan Adult Leukemia Study Group
Jin Takeuchi
Makoto Takeuchi
Masamitsu Yanada
Masayuki Towatari
Noriko Usui
Ryuzo Ohno
P304
P356
10.1182/BLOOD-2004-04-1389
P407
P577
2004-08-17T00:00:00Z